Condition: Acute Myeloid Leukemia · Myelodysplastic Syndromes · Mixed Phenotype Acute Leukemia · Sponsor: Orca Biosystems, Inc.
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.
This description comes directly from the study's public registry record.
Tamara Zharkevich, MD, PhD · 650-246-9601 · info@orcabiosystems.com
James S McClellan, MD PhD · 650-246-9601 · info@orcabiosystems.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| UC Davis | Sacramento, California, United States | Recruiting |
| Stanford Health Care | Stanford, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Active Not Recruiting |
| The University of Kansas Hospital | Kansas City, Kansas, United States | Withdrawn |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Active Not Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
| Froedtert Memorial Lutheran Hospital | Milwaukee, Wisconsin, United States | Withdrawn |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03802695